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Introduction: The insulin-like growth factor-1 receptor (IGF-1R) plays a key role in 
proliferation, growth, differentiation, and development of several human 
malignancies including breast and pancreatic adenocarcinoma. IGF-1R targeted 
immunotherapeutic approaches are particularly attractive, as they may potentially 
elicit even stronger antitumor responses than traditional targeted approaches. Cancer 
peptide vaccines can produce immunologic responses against cancer cells by 
triggering helper T cell (Th) or cytotoxic T cells (CTL) in association with Major 
Histocompatibility Complex (MHC) class I or II molecules on the cell surface of 
antigen presenting cells. 
 
Methods and Results: In our previous study, we set a technique based on molecular 
docking in order to find the best MHC class I and II binder peptides using GOLD. In 
the present work, molecular docking analyses on a library consisting of 30 peptides 
mimicking discontinuous epitopes from IGF-1R extracellular domain identified 
peptides 249 and 86, as the best MHC binder peptides to both MHC class I and II 
molecules. The receptors most often targeted by peptide 249 are HLA-DR4, HLA-
DR3 and HLA-DR2 and those most often targeted by peptide 86 are HLA-DR4, 
HLA-DP2 , and HLA-DR3. 
 
Conclusions: 
These findings, based on bioinformatics analyses, can be conducted in further 
experimental analyses in cancer therapy and vaccine design. 
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